Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
Sponsor: The University of Texas Medical Branch, Galveston • ClinicalTrials.gov ID: NCT05672927
Recruiting for Similar Conditions?
Sponsors are looking for patients like you. See if you qualify for compensated research studies.
Check Eligibility →Description
The goal of this clinical trial is to compare a 2-dose and 3-dose series of 9vHPV vaccine among 27-45-year-old females to assess if 2 doses elicit a noninferior immune response. Participants will be randomized 1:1 to either the 2-dose group or the 3-dose group and asked to provide 4 blood samples over a period of 12 months. All 2-dose participants will be offered a 3rd dose after the final blood draw,12 months after their initial vaccination.
Interventions
-
9-valent HPV vaccine, 2 doses alternate timing
(Biological)
Evaluate 2 doses of the 9-valent HPV vaccine across a 12-month period following the 1st dose among 27-45-year-old females.
-
9-valent HPV vaccine, 3 doses standard timing
(Biological)
This will be the comparison group for the 2-dose group.
Eligibility criteria
Conditions
Locations
- University of Texas Medical Branch — Galveston, Texas, United States
Partner with Nurenyx
Showcase your study to thousands of motivated patients matching your criteria.
Learn MoreOfficial Source
Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
View Official Record